Altimmune (ALT) Competitors

Altimmune (NASDAQ:ALT) and Pharvaris (NASDAQ:PHVS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings.

Do institutionals & insiders have more ownership in ALT or PHVS?

78.1% of Altimmune shares are held by institutional investors. 4.1% of Altimmune shares are held by insiders. Comparatively, 11.8% of Pharvaris shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Which has more volatility & risk, ALT or PHVS?

Altimmune has a beta of -0.01, meaning that its share price is 101% less volatile than the S&P 500. Comparatively, Pharvaris has a beta of -2.81, meaning that its share price is 381% less volatile than the S&P 500.

Which has better valuation and earnings, ALT or PHVS?

Altimmune has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Altimmune	$20K	15,825.02	-$95.06M	-$1.18	-3.04
Pharvaris	N/A	N/A	-$145.24M	-$3.36	-7.01

Does the media refer more to ALT or PHVS?

In the previous week, Altimmune had 20 more articles in the media than Pharvaris. MarketBeat recorded 42 mentions for Altimmune and 22 mentions for Pharvaris. Pharvaris' average media sentiment score of 0.81 beat Altimmune's score of 0.33 indicating that Pharvaris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Altimmune	8 Very Positive mention(s)	4 Positive mention(s)	20 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pharvaris	8 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is ALT or PHVS more profitable?

Pharvaris has a net margin of 0.00% compared to Altimmune's net margin of -438,730.03%. Altimmune's return on equity of -62.63% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Altimmune	-438,730.03%	-62.63%	-55.29%
Pharvaris	N/A	-69.09%	-63.34%

Do analysts prefer ALT or PHVS?

Altimmune currently has a consensus target price of $17.40, suggesting a potential upside of 385.22%. Pharvaris has a consensus target price of $35.60, suggesting a potential upside of 51.20%. Given Altimmune's higher probable upside, equities research analysts plainly believe Altimmune is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Altimmune	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Pharvaris	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

Altimmune beats Pharvaris on 10 of the 14 factors compared between the two stocks.